ENROLLING NOW A Phase 2 Clinical Study for Metastatic Non-Small Cell Lung Cancer (NSCLC)
LUN-202 is a Phase 2, multicenter clinical trial for patients whose current chemoimmunotherapy for NSCLC has stopped working.
The trial is determining whether an investigational one-time immunotherapy treatment using tumor infiltrating lymphocytes (TIL) is safe and effective for different types of patients with NSCLC.
Learn more about the trialTIL are part of the immune system. They are naturally occurring white blood cells that can recognize and destroy cancer cells.1
In TIL therapy, TIL are removed from a patient’s tumor, amplified and rejuvenated in a laboratory, and then reinfused into the patient to help the immune system recognize and destroy the cancer cells.1
All participants in the LUN-202 trial receive active treatment (there is no placebo arm). Study medication and study-related care are provided at no cost.
Reference: 1. Fardis M, DiTrapani K, Chartier C, Finckenstein FG. Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors. Cell Gene Ther Insights. 2020;6(6):855-863.